Platelet Factor 4 Inhibits IL-17/Stat3 Pathway via Upregulation of SOCS3 Expression in Melanoma

Inflammation

Volumn 37, Issue 5, 2014, Pages 1744-1750

  Fang, Shanshan ^a   Liu, Bo ^a   Sun, Qiushi ^a   Zhao, Juan ^a   Qi, Huixiong ^a   Li, Quan ^a  

^a HUBEI UNIVERSITY OF ARTS AND SCIENCE   (China)

Author keywords

IL 17 Stat3; melanoma; PF4; SOCS3

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 6; MESSENGER RNA; SMALL INTERFERING RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; THROMBOCYTE FACTOR 4; SOCS3 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; NONHUMAN; PROTEIN DNA BINDING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; MELANOMA, EXPERIMENTAL; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

MURINAE; MUS;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; INTERLEUKIN-17; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PLATELET FACTOR 4; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; UP-REGULATION;

EID: 84918768981     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9903-4     Document Type: Article

References (30)

1. Lambert, M.P., L. Rauova, M. Bailey, M.C. Sola-Visner, M.A. Kowalska, and M. Poncz. 2007. Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: Clinical and therapeutic implications. Blood 110: 1153–1160.
2. Arepally, G.M., S. Kamei, K.S. Park, K. Kamei, Z.Q. Li, W. Liu, D.L. Siegel, W. Kisiel, D.B. Cines, and M. Poncz. 2000. Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. Blood 95: 1533–1540.
3. Ziporen, L., Z.Q. Li, K.S. Park, P. Sabnekar, W.Y. Liu, G. Arepally, Y. Shoenfeld, T. Kieber-Emmons, D.B. Cines, and M. Poncz. 1998. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 92: 3250–3259.
4. Eslin, D.E., C. Zhang, K.J. Samuels, L. Rauova, L. Zhai, S. Niewiarowski, D.B. Cines, M. Poncz, and M.A. Kowalska. 2004. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: Dissociation between anticoagulant and antithrombotic effect of heparin. Blood 104: 3173–3180.
5. Aziz, K.A., J.C. Cawley, and M. Zuzel. 1995. Platelets prime PMN via released PF4: Mechanism of priming and synergy with GM-CSF. British Journal of Haematology 91: 846–853.
6. Engstad, C.S., K. Lia, O. Rekdal, J.O. Olsen, and B. Osterud. 1995. A novel biological effect of platelet factor 4 (PF4): Enhancement of LPS-induced tissue factor activity in monocytes. Journal of Leukocyte Biology 58: 575–581.
7. Sharpe, R.J., H.R. Byers, C.F. Scott, S.I. Bauer, and T.E. Maione. 1990. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. Journal of the National Cancer Institute 82: 848–853.
8. Maione, T.E., G.S. Gray, A.J. Hunt, and R.J. Sharpe. 1991. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Research 51: 2077–2083.
9. Kolber, D.L., T.L. Knisely, and T.E. Maione. 1995. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. Journal of the National Cancer Institute 87: 304–309.
10. Srivastava, K., I.A. Cockburn, A. Swaim, L.E. Thompson, A. Tripathi, C.A. Fletcher, E.M. Shirk, H. Sun, M.A. Kowalska, K. Fox-Talbot, et al. 2008. Platelet factor 4 mediates inflammation in experimental cerebral malaria. Cell Host & Microbe 4: 179–187.
11. Liu, C.Y., M. Battaglia, S.H. Lee, Q.H. Sun, R.H. Aster, and G.P. Visentin. 2005. Platelet factor 4 differentially modulates CD4 + CD25+ (regulatory) versus CD4 + CD25- (nonregulatory) T cells. Journal of Immunology 174: 2680–2686.
12. Shi, G., D.J. Field, K.A. Ko, S. Ture, K. Srivastava, S. Levy, M.A. Kowalska, M. Poncz, D.J. Fowell, and C.N. Morrell. 2014. Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection. Journal of Clinical Investigation 124: 543–552.
13. Kim, H.K., H. Zhang, H. Li, T.T. Wu, S. Swisher, D. He, L. Wu, J. Xu, C.A. Elmets, M. Athar, et al. 2008. Slit2 inhibits growth and metastasis of fibrosarcoma and squamous cell carcinoma. Neoplasia 10: 1411–1420.
14. Liang, P., S.H. Cheng, C.K. Cheng, K.M. Lau, S.Y. Lin, E.Y. Chow, N.P. Chan, R.K. Ip, R.S. Wong, and M.H. Ng. 2013. Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myeloma. Haematologica 98: 288–295.
15. He, D., H. Li, N. Yusuf, C.A. Elmets, J. Li, J.D. Mountz, and H. Xu. 2010. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. Journal of Immunology 184: 2281–2288.
16. Tang, Q., J. Li, H. Zhu, P. Li, Z. Zou, and Y. Xiao. 2013. Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma. Mediators of Inflammation 2013: 713859.
17. Wormald, S., and D.J. Hilton. 2004. Inhibitors of cytokine signal transduction. Journal of Biological Chemistry 279: 821–824.
18. Pandey, M.K., B. Sung, and B.B. Aggarwal. 2010. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. International Journal of Cancer 127: 282–292.
19. Gaffen, S.L. 2009. Structure and signalling in the IL-17 receptor family. Nature Reviews Immunology 9: 556–567.
20. He, D., L. Wu, H.K. Kim, H. Li, C.A. Elmets, and H. Xu. 2006. CD8+ IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses. Journal of Immunology 177: 6852–6858.
21. Kolls, J.K., and A. Linden. 2004. Interleukin-17 family members and inflammation. Immunity 21: 467–476.
22. Martin-Orozco, N., P. Muranski, Y. Chung, X.O. Yang, T. Yamazaki, S. Lu, P. Hwu, N.P. Restifo, W.W. Overwijk, and C. Dong. 2009. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31: 787–798.
23. Wakita, D., K. Sumida, Y. Iwakura, H. Nishikawa, T. Ohkuri, K. Chamoto, H. Kitamura, and T. Nishimura. 2010. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. European Journal of Immunology 40: 1927–1937.
24. Jarnicki, A., T. Putoczki, and M. Ernst. 2010. Stat3: Linking inflammation to epithelial cancer—more than a “gutˮ feeling? Cell Div 5: 14.
25. Catlett-Falcone, R., T.H. Landowski, M.M. Oshiro, J. Turkson, A. Levitzki, R. Savino, G. Ciliberto, L. Moscinski, J.L. Fernandez-Luna, G. Nunez, et al. 1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105–115.
26. Rebouissou, S., M. Amessou, G. Couchy, K. Poussin, S. Imbeaud, C. Pilati, T. Izard, C. Balabaud, P. Bioulac-Sage, and J. Zucman-Rossi. 2009. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457: 200–204.
27. Yu, H., and R. Jove. 2004. The STATs of cancer—new molecular targets come of age. Nature Reviews Cancer 4: 97–105.
28. Wang, L., T. Yi, M. Kortylewski, D.M. Pardoll, D. Zeng, and H. Yu. 2009. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. Journal of Experimental Medicine 206: 1457–1464.
29. Endo, T.A., M. Masuhara, M. Yokouchi, R. Suzuki, H. Sakamoto, K. Mitsui, A. Matsumoto, S. Tanimura, M. Ohtsubo, H. Misawa, et al. 1997. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387: 921–924.
30. Yoshimura, A., T. Naka, and M. Kubo. 2007. SOCS proteins, cytokine signalling and immune regulation. Nature Reviews Immunology 7: 454–465.